Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor ...

With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on ...

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

The firm said its upgrade reflects increased revenue forecasts for Vertex’s renal programs and higher valuation multiples, lifting its price target to $572. Bernstein sees a high probability that ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...